Find Amenamevir manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

FINISHED DOSAGE FORMULATIONS

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 841301-32-4, Asp 2151, Asp2151, Amenamevir [inn], Asp-2151, 94x46kw4ae
Molecular Formula
C24H26N4O5S
Molecular Weight
482.6  g/mol
InChI Key
MNHNIVNAFBSLLX-UHFFFAOYSA-N
FDA UNII
94X46KW4AE

Amenamevir
Amenamevir is a novel helicase-primase inhibitor that is active against varicella-zoster virus and herpes simplex virus types 1 and 2. Amenamenir stabilizes the interaction between the helicase-primase and its DNA substrates, preventing the progression through helicase or primase catalytic cycles, thus interfering with viral DNA replication and viral growth.
1 2D Structure

Amenamevir

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-(2,6-dimethylphenyl)-N-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide
2.1.2 InChI
InChI=1S/C24H26N4O5S/c1-16-4-3-5-17(2)22(16)28(24(30)19-10-12-34(31,32)13-11-19)14-21(29)26-20-8-6-18(7-9-20)23-25-15-33-27-23/h3-9,15,19H,10-14H2,1-2H3,(H,26,29)
2.1.3 InChI Key
MNHNIVNAFBSLLX-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC1=C(C(=CC=C1)C)N(CC(=O)NC2=CC=C(C=C2)C3=NOC=N3)C(=O)C4CCS(=O)(=O)CC4
2.2 Other Identifiers
2.2.1 UNII
94X46KW4AE
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Asp2151

2.3.2 Depositor-Supplied Synonyms

1. 841301-32-4

2. Asp 2151

3. Asp2151

4. Amenamevir [inn]

5. Asp-2151

6. 94x46kw4ae

7. N-(2-((4-(1,2,4-oxadiazol-3-yl)phenyl)amino)-2-oxoethyl)-n-(2,6-dimethylphenyl)tetrahydro-2h-thiopyran-4-carboxamide 1,1-dioxide

8. N-(2,6-dimethylphenyl)-n-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxoethyl]-1,1-dioxothiane-4-carboxamide

9. Unii-94x46kw4ae

10. Amenalief (tn)

11. Amenamevir [mi]

12. Amenamevir (jan/inn)

13. Amenamevir [jan]

14. Amenamevir [who-dd]

15. Schembl2238614

16. Chembl4297592

17. Dtxsid101027753

18. Bcp29135

19. Ex-a1700

20. S5552

21. Ccg-269570

22. Cs-8093

23. Db11701

24. Sb19732

25. Ncgc00538163-01

26. Ac-35855

27. Bs-17608

28. Hy-14809

29. D10564

30. D84108

31. Q27271708

32. 2-[n-(2,6-dimethylphenyl)-n-[(tetrahydro-2h-thiopyran 1,1-dioxide)-4-ylcarbonyl]amino]-4'-(1,2,4-oxadiazole-3-yl)acetoanilide

33. N-(2,6-dimethylphenyl)-n-(2-((4-(1,2,4-oxadiazol-3-yl)phenyl)amino)-2-oxoethyl)-1,1-dioxothiane-4-carboxamide

34. N-(2,6-dimethylphenyl)-n-(2-{[4-(1,2,4-oxadiazol-3-yl)phenyl]amino}-2-oxoethyl)tetrahydro-2h-thiopyran-4-carboxamide 1,1-dioxide

35. N-(2,6-dimethylphenyl)-n-[2-[4-(1,2,4-oxadiazol-3-yl)anilino]-2-oxo-ethyl]-1,1-dioxo-thiane-4-carboxamide

2.4 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 482.6 g/mol
Molecular Formula C24H26N4O5S
XLogP32.6
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count7
Rotatable Bond Count6
Exact Mass482.16239112 g/mol
Monoisotopic Mass482.16239112 g/mol
Topological Polar Surface Area131 Ų
Heavy Atom Count34
Formal Charge0
Complexity800
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 ATC Code

J - Antiinfectives for systemic use

J05 - Antivirals for systemic use

J05A - Direct acting antivirals

J05AX - Other antivirals

J05AX26 - Amenamevir


INTERMEDIATES SUPPLIERS

read-more
read-more

01

BioFlorida Conference
Not Confirmed
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

CAS Number : 89489-53-2

End Use API : Amenamevir

About The Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our cor...

Jinan Tantu Chemicals

02

BioFlorida Conference
Not Confirmed
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

CAS Number : 64096-87-3

End Use API : Amenamevir

About The Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our cor...

Jinan Tantu Chemicals

03

BioFlorida Conference
Not Confirmed
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothJinan Tantu Chemicals offers customized R&D services & production of small molecule APIs & pharmaceutical intermediates.

CAS Number : 59908-70-2

End Use API : Amenamevir

About The Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our cor...

Jinan Tantu Chemicals
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Listed Dossiers

read-more
read-more

01

Maruho

Japan
BioFlorida Conference
Not Confirmed
arrow

Maruho

Japan
arrow
BioFlorida Conference
Not Confirmed

Amenamevir

Brand Name : Amenalief

Dosage Form : Tablet

Dosage Strength : 200MG

Packaging :

Approval Date :

Application Number :

Regulatory Info :

Registration Country : Japan

blank

01

Maruho

Japan
BioFlorida Conference
Not Confirmed
arrow

Maruho

Japan
arrow
BioFlorida Conference
Not Confirmed

Amenamevir

Dosage : Tablet

Dosage Strength : 200MG

Brand Name : Amenalief

Approval Date :

Application Number :

Registration Country : Japan

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.tantuchemicals.com/news/revarazan-hcl-for-acute-gastritis-chronic-gas-76202020.html

PRESS RELEASE
28 Mar 2024

https://www.tantuchemicals.com/news/jinan-tantu-chemicals-co-ltd-has-completed-72343522.html

PRESS RELEASE
08 Nov 2023

https://cfpharma.hu/atropisomerism-investigation/

PRESS RELEASE
31 Aug 2023

Market Place

Do you need sourcing support? Ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty